Population-based cohort studies conducted in highincome countries have demonstrated that HIV infection is an independent risk factor for stroke.
1-3 A prospective community-based case-control study of stroke risk factors in Tanzania reported that HIV seropositivity is an independent risk factor, with an adjusted odds ratio (OR) of 5.61. 4 Most studies have focused on the association of HIV infection with ischemic stroke (IS). Reviewing the limited number of studies addressing intracerebral hemorrhage (ICH), HIV infection appears to increase the risk of ICH even greater than that of IS. [5] [6] [7] While the strength of the associations and the pathogenic mechanisms remain matters of debate, autopsy studies evaluating the cerebral vasculature in HIV-infected patients demonstrate a variety of pathologic changes. Small vessels appear to develop a vasculopathy, with perivascular space dilation, rarefaction, pigment deposition, vessel wall mineralization, and perivascular cell infiltrates, all without evidence of a vasculitis. 8 In larger cerebral vessels, progressive vessel dilation occurs in HIV infection, potentially mediated by a thinner media layer leading to aneurysm formation. 9 Additionally, there is evidence for increased arterial inflammation and carotid atherosclerosis in the setting of HIV infection. 10, 11 These vascular changes could certainly disrupt cerebral autoregulation, diminish vessel wall tensile strength, and disrupt blood-brain barrier function, resulting in an increased risk of stroke. Although the biological mechanisms underlying the increased risk of ICH and IS in HIV-infected individuals likely overlap, there may be distinct mechanisms for each stroke subtype that are population-specific or manifest in the presence of other medical conditions and traditional stroke risk factors.
In this issue of Neurology ® , Chow et al. 12 directly address our knowledge gap in this area by comparing rates of ICH in HIV-infected and uninfected individuals in a large clinical care cohort (n 5 39,519) and assessing the risk factors associated with ICH. Cases and controls from the Partners HealthCare System (Boston, MA) were identified with incident ICH and stratified by HIV infection status (4,251 were HIV-infected). Analyses using Cox proportional hazards models were implemented to estimate adjusted hazard ratios for HIV infection and other predictors of ICH. The median duration of follow-up was 5.47 years. The incidence rate of ICH was 2.29 per 1,000 person-years in HIV-infected individuals compared with 1.23 per 1,000 person-years in uninfected individuals, with an unadjusted incidence rate ratio of 1.85 (95% confidence interval 1.37-2.47, p , 0.001). In a multivariable model, HIV infection was independently associated with a higher hazard of ICH, with the effect diminishing with increasing age. Female sex was associated with a lower hazard ratio of ICH in the uninfected cohort but was not protective for ICH among the HIV cohort. As expected, hypertension and anticoagulant use were predictive of ICH. Similar to findings from previous studies demonstrating an increased risk of IS with HIV infection, 2, 3 advanced immunosuppression (CD4 count ,200 3 10 6 cells/L) was associated with a markedly higher risk of ICH.
The results of this study should be interpreted in light of the intrinsic limitations of a cohort database study design. Beyond the unmeasured confounding that can occur in any observational study, there are limitations related to the use of ICD-9-CM codes (diagnostic codes used in the United States, identified by providers). 13 While ICD-9 codes can provide a reasonable surrogate for diagnoses, their validity was not assessed directly, neither for the HIV-positive or HIV-negative cohorts. Rates of ICH were higher in this cohort than previously published estimates, a finding that may reflect misclassification by ICD-9-CM codes or a referral center bias. The investigators did not have information on the size, location, or severity of the ICH and could not distinguish between ICH and hemorrhagic conversion of ischemic strokes. They lacked data on hypertension stage, duration of HIV infection, illicit drug use, and obesity. Finally, the Partners HealthCare System HIVinfected cohort may differ from the populations of people living with HIV in the United States and in other countries, although nonwhite participants and women were well-represented.
Chow et al. have added to the growing body of evidence that HIV confers an independent risk for both ICH and IS. Further investigation into the mechanisms driving these associations is warranted. Clinicians should focus their preventive efforts on traditional modifiable stroke risk factors, including hypertension, smoking, diabetes, dyslipidemia, and obesity. HIV serostatus should be determined for all stroke patients. The potential benefits of early initiation and optimization of combination antiretroviral therapy, according to WHO and national guidelines, should now include the primary and secondary prevention of stroke.
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